$TBPH News

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Theravance Biopharma Q2 Adj. EPS $0.18 Beats $0.05 Estimate, Sales $20.731M Miss $21.600M Estimate

HC Wainwright & Co. Downgrades Theravance Biopharma to Neutral, Raises Price Target to $17

Jones Trading Downgrades Theravance Biopharma to Hold

BTIG Downgrades Theravance Biopharma to Neutral

Are Options Traders Betting on a Big Move in Theravance Biopharma Stock?

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Theravance Biopharma Q1 EPS $(0.10) Misses $0.03 Estimate, Sales $17.699M Beat $17.200M Estimate

Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised

Laughing Water Capital’s New Position: Theravance Biopharma (TBPH)

Theravance Biopharma: A Special Situation With A 50-100% Likely Upside

B. Riley Securities Maintains Neutral on Theravance Biopharma, Raises Price Target to $17

Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics

5 Small Drug Stocks to Buy as Sector Recovery Gains Strength

TD Cowen Maintains Hold on Theravance Biopharma, Raises Price Target to $15

All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong Buy

BTIG Reiterates Buy on Theravance Biopharma, Maintains $21 Price Target

Theravance Bio: Q4 Earnings Snapshot

Theravance Biopharma Q4 EPS $1.15 Beats $1.02 Estimate, Sales $45.891M Miss $50.793M Estimate